CD4 and neoplasm: Taken together, the data suggest combined immunotherapy and Trp2Vax treatment increased frequency and effector functions of tumor-infiltrating effector cells (CD4+ and CD8+ T cells an NK cells), and potentially activate APCs such as macrophages for antigen presentation.